Cipla Lumartem Artemether and Lumefantrine Tablet SmPC

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

 

1. NAME OF THE MEDICINAL PRODUCT

Lumartem

 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each uncoated tablet contains:

Artemether Ph. Int. 20 mg

Lumefantrine 120 mg

For a full list of excipients see section 6.1.

 

3. PHARMACEUTICAL FORM

Yellow, circular, flat, bevelled, uncoated tablets with a central breakline on one side and plain on other side.

The breakline is only to facilitate breaking for ease of swalloning and not to divide into equal doses.

Specific embossings may be required for certain countries. Reference is made to the conditions for approval of the national drug regulatory authorities.

 

4. CLINICAL PARTICULARS

4.1 Therapeutic Indication

Lumartem is indicated for the treatment of uncomplicated cases of malaria due to Plasmodium falciparum in adults, children and infants of 5 kg and above.

The most recent official guidelines on the appropriate use of antimalarial agents and local information on the prevalence of resistance to antimalarial drugs must be taken into consideration for deciding on the appropriateness of therapy with Lumartem.
Official guidance will normally include WHO (http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf) and local health authorities’ guidelines (see also sections 4.4 and 5.1).

 

4.2 Posology and method of administration

Tablets for oral administration.

Number Lumartem for treatment according to weight bands.

Weight range 1st day
of treatment
2nd day
of treatment
3rd day
of treatment
> 5kg to < 15kg 1 tablet twice daily (2 x 20mg/120mg
A/L)
1 tablet twice
daily (2 x 20mg/120mg
A/L)
1 tablet twice
daily (2 x 20mg/120mg A/L)
15kg to <25kg 2 tablets twice
daily (2 x 40mg/240mg
A/L)
2 tablets twice
daily (2 x 40mg/240mg
A/L)
2 tablets twice
daily (2 x 40mg/240mg
A/L)
25kg to <35kg 3 tablets twice
daily (2 x 60mg/360mg
A/L)
3 tablets twice
daily (2 x 60mg/360mg
A/L)
3 tablets twice
daily (2 x 60mg/360mg
A/L)
≥35kg (or
≥12 years
of age
4 tablets twice
daily (2 x 80mg/480mg
A/L)
4 tablets twice
daily (2 x 80mg/480mg
A/L)
4 tablets twice
daily (2 x 80mg/480mg
A/L)

Treatment should be administered at the time of initial diagnosis or at the onset of symptoms. It is preferable that the patient has a positive diagnostic test before administration.

The first dose should be followed by a second dose after 8 hours. The following two days the doses of Lumartem should be given twice daily, morning and evening (i.e. 12 hours apart).

To Increase absorption, Lumartem should be taken with food or a milky drink (see section 5.2). If a patient is unable to tolerate food, Lumartem should still be administered, but the systemic exposure may be reduced. Patients who vomit within 1 hour of taking the medication should repeat the dose.

The tablets can also be crushed and administered with food or a milky drink.

Renal or hepatic impairment

No dose adjustments are necessary in patients with renal or hepatic impairment.

However, caution is advised when administering Lumartem to patients with severe renal or hepatic problems (see setion 4.4).

Elderly

No special precautions or dosage adjustments are necessary in such patients.

 

4.3 Contraindications

Hypersensitivity to artemether, lumefantrine or to any of the excipients.

 

4.4 Special warnings and precautions for use

Pregnancy

Lumartem should not be used in the first trimester of pregnancy in situations where other suitable and effective antimalarials are available (see section 4.6).

Prolongation of the QT-interval

Lumartem may prolong the QTc interval and increase the risk of cardiac arrhythmias (see sections 4.5, 4.8 and 5.1). Therefore Lumartem should be avoided in patients:

– with a family history of congenital prolongation of the QTc interval or sudden death, or with any other clinical condition known to prolong the QTc interval, such as patients with a history of symptomatic cardiac arrhythmias, clinically relevant bradycardia or congestive heart failure.

– with known disturbances of electrolyte balance, e.g. hypokalaemia or hypomagnesaemia.

– taking drugs that prolong the QTc interval, such as class IA and III antiarrhythmics, certain neuroleptics and antidepressants, certain antibiotics (some macrolides and fluoroquinolones), certain non-sedating antihistamines (terfenadine, astemizole) and cisapride.

– taking drugs with narrow therapeutic index which are metabolized by cytochrome CYP2D6 (e.g. flecainide, metoprolol, imipramine, amitriptyline, clomipramine).
In these patients, ECG- and serum potassium-monitoring is advised.

Renal/hepatic dysfunction

Lumartem has not been studied in patients with severe renal or hepatic problems.

Severe malaria

Lumartem has not been evaluated for the treatment of severe malaria, including cases of cerebral malaria or other severe manifestations such as pulmonary oedema or renal failure. Use of Lumartem in such cases is also inadvisable on pharmacokinetic grounds, as it is uncertain if exposure of artemether and, in particular, of lumefantrine is adequate in these patients with high parasitaemia and little or no food intake.

Malaria prophylaxis

Lumartem has not been evaluated for malaria prophylaxis.

Malaria not caused by P falciparum

Lumartem has not been evaluated for the treatment of malaria due to P vivax, P malariae , P ovale or P knowlesi (see section 5.1).

Following treatment of mixed infections including P vivax, follow-up treatment must be given in order to eradicate the exoerythrocytic forms of P vivax.

Other antimalarials

Unless there is no other treatment option, Lumartem should not be given concurrently with any other antimalarial agent due to limited data on safety and efficacy (see section 4.5).

If a patient deteriorates while taking Lumartem, alternative treatment for malaria should be started without delay. In such cases, monitoring of the ECG is recommended and steps should be taken to correct any electrolyte disturbances. Due to the potential of additive/synergistic QT-prolongation, close ECG monitoring is advised when quinine is given after Lumartem (see section 5.1).

If Lumartem is given after mefloquine, close monitoring of food intake is advised (see section 4.5).

In patients previously treated with halofantrine, Lumartem should not be administered earlier than one month after the last halofantrine dose (see section 4.5).

Hormonal contraceptives

Lumartem may reduce the effectiveness of hormonal contraceptives. Patients should be advised to use additional non-hormonal method of birth control.

Intake with food and drinks

Patients who remain averse to food during treatment should be closely monitored, as the risk of recrudescence may be greater.

 

4.5 Interactions with other medicinal products and other forms of interaction

Lumartem should not be used in patients taking drugs that are known to prolong the QTc interval (see section 4.4), as effects may be additive and increase the risk of cardiac arrhythmia.

Interaction with other antimalarials

Lumartem should not be given concurrently with any other antimalarial agent (see section 4.4). In addition, due to the propensity of some antimalarial agents to prolong the QTc interval, caution is advised when administering Lumartem to patients in whom there may still be detectable concentrations of these drugs in the plasma following prior treatments.

Administration of a six-dose regimen of artemether/lumefantrine (over 60 hours) starting 12 hours after completion of a three-dose regimen of mefloquine or placebo in healthy volunteers showed no effect of mefloquine on plasma concentrations of artemether or the artemether/dihydroartemisinin ratio, but a 30-40% reduction in plasma levels of lumefantrine. These are possibly due to lower absorption secondary to mefloquine-induced decrease in bile production. Patients that have been protreated with mefloquine should be encouraged to eat at dosing times to compensate for the decrease in bioavailability. Plasma mefloquine concentrations from the time of addition of artemether/lumefantrine were not affected compared with a group that received mefloquine followed by placebo.

In patients previously treated with halofantrine, Lumartem should be dosed at least one month after the last halofantrine dose due to the long elimination half-life of halofantrine and the potential additive/synergistic effects on the QT-interval.

Interaction with CYP450 enzymes

Studies in humans have demonstrated that artemisinins have some capacity to induce CYP3A4 and CYP2C19 and inhibit CYP2D6 and CYP1A2. Although the magnitude of the changes was generally low it is possible that these effects could alter the therapeutic response or safety profile of drugs that are predominantly metabolised by these enzymes (see sections 4.4 and 5.2).

Lumefantrine was found to inhibit CYP2D6 in vitro. This may be of particular clinical relevance for compounds with a low therapeutic index (see section 4.3).

Interaction with CYP450 3A4 inhibitors

Ketonazole

Both artemether and Iumefantrine are metabolised predominantly by the cytochrome enzyme CYP3A4, and do not inhibit this enzyme at therapeutic concentrations. The concurrent oral administration of ketoconazole with artemether/lumefantrine led to a modest increase (2 fold) in artemether, DHA, and lumefantrine exposure in healthy adult subjects. This increase in exposure to the antimalarial combination was not associated with increased side effects or changes in electrocardiographic parameters. Dose adjustment of Lumartem is not considered necessary when administered concomitantly with ketoconazole or other azole antifungals, but such combinations should be used with caution.

HIV protease inhibitors

When co-administered with lopinavir and ritonavir, the AUC of lumefantrine increased by 193% and the Cmax by 82%. Arthemeter and lumefantrine did not significantly affect lopinavir exposure. Data for other protease inhibitors are not available. Lumartem and HIV protease inhibitors should be coadministered with caution.

 

4.6 Pregnancy and lactation

Pregnancy

There is insufficient data from the use of artemether and lumefantrine in pregnant women. In animal studies Lumartem, as well as other artemisinin derivates, have been shown to cause post-implantation losses and serious birth defects when administered during the first trimester of pregnancy (see sections 4.4 and 5.3). Therefore, Lumartem should not be used during the first trimester of pregnancy in situations where other suitable and effective antimalarials are available (see section 4.4). Nonetheless, it may be used when it is the only treatment immediately available.

Lactation

The amounts of artemether, dihydroartemisinin and lumefantrine in breast milk are small. Therefore, lactating women can receive artemisinin-based combination therapies (including Lumartem) for malaria treatment.

 

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability-to drive and use machine have been performed. Patients receiving Lumartem should be warned that dizziness, fatigue or asthenia may occur, in which case their ability to drive or operate machines may be impaired.

 

4.8 Undesirable effects

The safety of artemether/lumefantrine has been evaluated in clinical trials with more than 3500 patients. A total of 1810 adults and adolescents above 12 years of age as well as 1788 infants and children of 12 years of age and below have received artemether/lumefantrine in clinical trials.

Adverse reactions reported from clinical studies and post-marketing experience are listed below according to system organ class.

Adverse reactions are ranked under headings of frequency using the MedDRA frequency convention:

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000)

Not known (cannot be estimated from available data).

Table 1: Frequency of undesirable effects

Adults and adolescents above 12 years of age Infants and children of 12 years of age and below (Incidence estimates*)
Cardiac disorders
Palpitations Very common Common
Electrocardiogram QT prolonged Common Common
Nervous system disorders
Headache Very common Very common
Dizziness Very common Common
Paraesthesia Common
Gait disturbance Common
Ataxia, hypoaesthesia Uncommon
Clonic movements, somnolence Uncommon Uncommon
Respiratory, thoracic and mediastinal disorders
Cough Common Very common
Gastrointestinal disorders
Vomiting Very common Very common
Abdominal pain Very common Very common
Nausea Very common Common
Anorexia Very common Very common
Diarrhoea Common Common
Skin and subcutaneous tissue disorders
Rash Common Common
Pruritus Common Common
Urticaria, angioedema* Not common Not common
Arthralgia Very common Common
Myalgia Very common Common
General disorders and administration site conditions
Asthenia Very common Common
Fatigue Very common Common
Immune system disorders
Hypersensitivity Not known Rare
Hepatobiliary disorders
Liver function tests increased Uncommon Common
Psychiatric disorders
Sleep disorders Very common Common
Insomnia Common Uncommon

* These adverse reactions were reported during post-marketing experience. Because these spontaneously reported events are from a population of uncertain size, it is difficult to estimate their frequency.

 

4.9 Overdose

Experience of overdosage with artemether and lumefantrine is limited. In cases of suspected overdosage symptomatic and supportive therapy should be given as appropriate, which should include monitoring of ECG and serum electrolytes.

 

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antimalarials, blood schizonticide, ATC code: P01 BE52

Pharmacodynamic effects

Lumartem comprises a fixed ratio of 1:6 parts of artemether and lumefantrine, respectively. The site of antiparasitic action of both components is the food vacuole of the malarial parasite, where they are thought to interfere with the conversion of haem, a toxic intermediate produced during haemoglobin breakdown, to the nontoxic haemozoin, malaria pigment. Lumefantrine is thought to interfere with the polymerisation process, while artemether generates reactive metabolites as a result of the interaction between its peroxide bridge and haem iron. Both artemether and lumefantrine have a secondary action involving inhibition of nucleic acid- and protein synthesis within the malarial parasite.

The antimalarial activity of the combination of lumefantrine and artemether in Lumartem is greater than that of either substance alone. In a double-blind comparative study in adults in China (n=157), the 28-day cure rate of artemether/lumefantrine when given at four doses was 94% compared with 90% for lumefantrine and 46% for artemether based on intent-to-treat (ITT) population, when given as monotherapy. For the evaluable population, 28-day cure rates were 100% for artemether/lumefantrine, compared with 92% for lumefantrine and 55% for artemether when given as monotherapy.

In areas where multi-drug-resistant strains of P falciparum malaria are common and in the resident population, 28-day cure rates with the 6 dose regimen (given over 60 to 96 h) were 81% and 90% for artemether/lumefantrine versus 94% and 96% for mefloquine/artesunate, based on the ITT population. For the evaluable population, 28-day cure rates were 97% and 95% for artemether/ lumefantrine and 100% for mefloquine/artesunate.

In an open, multicenter clinical study conducted in Africa in 310 children weighing 5 kg to less than 25 kg and receiving a six-dose artemether/ lumefantrine regimen according to their body weight range, the mean 28-day parasitological cure rate (PCR-corrected) was 93.9% for the ITT population and 96.7% for the evaluable population.

In non-immune patients living in regions free of malaria but with malaria acquired when travelling in endemic regions, a similar efficacy and safety profile was shown. In an open study (n=165) in adults the 28-day cure rate for artemether/lumefantrine given as the six-dose regimen was 96% (119/124) for the evaluable and 74.1% (120/162) for the ITT population. The main causes of the difference between the evaluable and ITT cure rates were “lost to follow up” (33 patients) or protocol violations (intake of prohibited concomitant medications). These two groups were considered as treatment failures in the ITT analysis.

Arthemeter/lumefantrine is active against blood stages of Plasmodium vivax, but is not active against hypnozoites.

QT/QTc Prolongation

For information on the risk of QT/QTc prolongation in patients see section 4.4.

In a healthy adult volunteer parallel group study including a placebo and moxifloxacin control group (n=42 per group), the administration of the six dose regimen of artemether/lumefantrine with food was associated with a moderate prolongation of QtcF (QT interval corrected by Fridericias formula). The mean changes from baseline at 68, 72, 96, and 108 hours post first dose were 7.45, 7.29, 6.12 and 6.84 msec, respectively. At 156 and 168 hours after first dose, the changes from baseline for QTcF had no difference from zero. No subject had a > 30 msec increase from baseline nor an absolute increase to > 500 msec. Moxifloxacin control was associated with a QTcF increase as compared to placebo for 12 hours after the single dose with a maximal change at 1 hour after dose of 14.1 msec.

 

5.2 Pharmacokinetic properties

Artemether

Absorption
Artemether is absorbed fairly rapidly and dihydroartemisinin (DHA), the active metabolite of artemether, appears rapidly in the systemic circulation with peak plasma concentrations of both compounds reached about 2 hours after dosing. The absolute bioavailability is unknown.

Following single dose administration of 4 tablets of Lumartem in healthy volunteers, the mean (± SD) artemether Cmax value was 119 (±54) ng/ml, the corresponding value for AUC was 349 (±164) ng.h/ml, and the mean artemether tmax value was 2.5 (±0.9) hours. The pharmacokinetic data for dihydroartemisinin were supportive and indicated a comparable bioavailability between Test and Reference.

In healthy volunteers the relative bioavailability of artemether was increased more than two-fold when taken with food.

Distribution

Artemether is 95.4% bound to human serum proteins in vitro. The active metabolite dihydroartemisinin (DHA) is also bound to human serum proteins (47-76%).

Metabolism

Artemether is rapidly and extensively metabolised with substantial first-pass metabolism. Artemether is metabolised in the liver to the biologically active main metabolite DHA (demethylation), predominantly through the isoenzyme CVP3A4/5. The pharmacokinetics of artemether in adults is time-dependent. During repeated administration of arthemeter/lumefantrine, plasma artemether levels decreased significantly, while levels of the active metabolite (dihydroartemisinin) increased, although not to a statistically significant degree. The ratio of day 3/day 1 AUC for artemether was between 0.19 and 0.44, and was between 1.06 and 2.50 for dihydroartemisinin. This suggests that there was induction of the enzyme responsible for the metabolism of artemether. DHA is further converted to inactive metabolites, primarily by glucuronidation. In vivo data indicate that artemisinins have some capacity to induce cytochrome isoenzymes CYP2C19 and CYP3A4.

Elimination

Artemether and dihydroartemisinin are rapidly cleared from plasma with an elimination half-life of about 2 hours.

No urinary excretion data are available for humans. In rats and dogs unchanged artemether has not been detected in faeces and urine due to its rapid and high-first-pass metabolism, but several metabolites (unindentified) have been detected in both faeces and urine.

Lumefantrine

Absorption

Absorption of lumenfantrine, a highly lipophilic compound, starts after a lag-time of up to 2 hours, with peak plasma concentration about 6-8 hours after dosing. The absolute bioavailability is unkown. Following single dose administration of 4 tablets of Lumartem in healthy volunteers, the mean (±SD) luemfantrine Cmax value was 4,9 (V2.5) µg.h/ml, and the mean lumefantrine tmax value was 6.0 (±0.8) hours. In healthy volunteers the relative bioavailability of lumefantrine, when taken after a high-fat meal, was increased sixteen-fold compared with fasted conditions. Food has also been shown to increase the absorption of lumefantrine in patients with malaria, although to a lesser extent (approximately two-fold), most probably due to the lower fat content of the food ingested by acutely ill patients. The food interaction data indicate that absorption of lumefantrine under fasted conditions is very poor. Patients should therefore be encouraged to take the medication with a normal diet as soon as food can be tolerated.

Distribution

Lumefantrine is 99.7% bound to human serum proteins in vitro.

Metabolism

Lumefantrine is N-debutylated, mainly by CYP3A4, in human liver microsomes. The systemic exposure to the metabolite desbutyl-lumefantrine, for which the in vitro antiparasitic effect is 5 to 8 fold higher than lumefantrine, was less than 1% of the exposure to the parent drug. Desbutyl-lumefantrine data is not available specifically for an African population. In vitro, lumefantrine significantly inhibits the activity of CYP2D6 at therapeutic plasma concentrations. In humans, the exposure to lumefantrine increases with repeated administration of arthemeter/lumefantrine over the 3-day treatment period, consistent with the slow elimination of the compound.

Elimination

Lumefantrine is eliminated very slowly with a terminal half-life of approximately 3 days. No urinary excretion data are available for humans. Lumefantrine is eliminated via the bile in rats and dogs, with excretion primarily in the faeces. After oral dosing in rats and dogs qualitative and quantitative recovery of metabolites in bile and faeces was relatively low, most of the dose being recovered as parent drug.

Pharmacokinetics in special patient populations

Specific pharmacokinetic studies have not been performed in patients with hepatic or renal insufficiency. No pharmacokinetic studies are available in elderly patients.

Paediatric population

In paediatric malaria patients, mean Cmax (CV%) of artemether (observed after first dose) were 223 (139%), 198 (90%) and 174 ng/mI (83%) for body weight groups 5-<15, 15-<25 and 25-<35 kg, respectively, compared to 186 ng/ml (67%) in adult malaria patients. The associated mean Cmax of DHA were 54.7 (108%), 79.8 (101%) and 65.3 ng/ml (36%), respectively compared to 101 ng/ml (57%) in adult malaria patients.

AUC of lumefantrine (population mean, covering the six doses of artemether/ lumefantrine) were 577, 699 and 1150 µg.h/mI for paediatric malaria patients in body weight groups 5-<15, 15-<25 and 25-<35 kg, respectively, compared to a mean AUC of 758 µg.h/ml (87%) in adult malaria patients. The elimination half-lives of artemether and lumefantrine in children are unknown.

 

5.3 Preclinical safety data

General toxicity

The main changes observed in repeat-dose toxicity studies were associated with the expected pharmacological action on erythrocytes, accompanied by responsive secondary haematopoiesis.

Mutagenicity

No evidence of mutagenicity was detected in vitro or in vivo tests with an artemether:lumefantrine combination (consisting of 1 part artemether:6 parts lumefantrine). In the micronucleus test myelotoxicity was seen at all dose levels (500, 1,000 and 2,000 mg/kg), but recovery was almost complete 48 hours after dosing.

Carcinogenicity

Carcinogenicity studies with the artemether/lumefantrine combination were not conducted.

Reproductive toxicity studies

Reproductive toxicity studies performed with the artemether/lumefantrine combination caused maternal toxicity and increased post-implantation loss in rats and rabbits at doses 50 mg/kg/day (corresponding to approximately 7 mg/kg/day artemether) and 175 mg/kg/day (corresponding to 25 mg/kg/day artemether) respectively. These effects were not observed at lower doses.

Lumefantrine alone caused no sign of reproductive or development toxicity at doses up to 1,000 mg/kg/day in rats and rabbits.

Embryotoxicity has been observed in rat and rabbit reproductive toxicity studies conducted with artemether, a derivative of artemisinin. Artemisinins (e.g. artesunate) are known to be embryotoxic.

Artemether caused increases in post-implantation loss and teratogenicity (characterised as a low incidence of cardiovascular and skeletal malformations) in rats at 19.4 mg/kg, and in rabbits at 30 mg/kg. Maternal toxicity was also observed in rabbits at 30 mg/kg/day. No other adverse effects were observed at lower doses in rabbits. The no observed effect dose was 3 mg/kg/day in rats and 25 mg/kg/day in rabbits.

The embryotoxic artemether dose, 20 mg/kg/day in the rat, yields artemether and dihydroartemisinin exposures similar to those achieved in humans.

Artesunate, a structurally related compound, also caused increases in post-implantation loss and teratogenicity (low incidence of cardiovascular and skeletal malformations) in rats at 6 mg/kg and in the lowest dose tested in the rabbits, 5 mg/kg/day.

Cardiovascular Pharmacology

In toxicity studies in dogs at doses > 600 mg/kg/day only, there was some evidence of prolongation of the QTc interval, at higher doses than intended for use in man. In an in vitro assay of HERG channels, lumefrantrine and the main metabolite desbutyl-lumefantrine showed some inhibitory potential in one of the currents responsible for cardiac repolarization. From the estimated IC5O values, the order of potency of HERG current block was halofantrine (IC50 = 0.04 µM)

> chloroquine (2.5 µM) > mefloquine 2.6 µM) > desbutyl-lumefantrine (5.5 µM).

> lumefantrine (8.1 µM). Clinical studies show, that prolongation of QTcF can occur with standard dosing of artemether/lumefantrine (see sections 4.4 and 5.1).

 

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

Croscarmellose sodium

Magnesium stearate

Maize starch

Microcrystalline cellulose

Polysorbate 80

Purified talc.

 

6.2 Incompatibilities

Not applicable.

 

6.3 Shelf life

24 months.

 

6.4 Special precautions for storage

Do not store above 30°C. Protect from light. Store in the original package.

 

6.5 Nature and contents of container

The primary packs are:

• Aluminium-aluminium blister foils. Pack sizes: packs of 1×6 (6), 2×6 (12), 3×6 (18) or 4×6 (24) tablets.

• Aluminium blister foil and a clear transparent, well thermoformable PVC/PCTFE film

• Pack size: Packs of 6, 12, 18 or 24 tablets.

 

6.6 Special precautions for disposal

Not applicable.

 

7. Supplier

Cipla Ltd

289, JBB Marg

Mumbai Central

Mumbai 400 008

India

exports@cipla.com

8. WHO Reference Number (Prequalification Programme)

MA064

 

9. Date of First Prequalification

22 May 2009

 

10. Date of Revision of the Text

September 2010. Sections 3 and , 4 updated in March 2012.

 

NAFDAC REG. NO.: A4-4845

 

CIPLA LTD.

Plot 9 & 10, Indore SEZ

Pithampur, M.P.-454 775, INDIA.